Remissions in Patients with Idiopathic Membranous NephropathyTreated with Rituximab in Senegal

Objectives: this study aimed to evaluate the eÿcacy of rituximab in the management of idiopathic membranous nephropathy (imn) based on the following criteria: (i) biological remission at three months (m3) and six months (m6); (ii) change in mean pro-teinuria (24pu), mean serum albumin, and mean serum creatinine at m3 and m6; (iii) and side e ects.methods: this retrospective descriptive and analytical study included patients with histologically confirmed imn with positive plasma anti-pla2r antibodies who received at least one dose of rituximab after six months of follow-up without spontaneous re-mission. patients with unexplainable records were not included.results: a total of five patients (p1, p2, p3, p4, and p5), including four males and one female were analyzed. the mean age was 44.20± 23.14 years. all patients had imn type 2. at inclusion, the mean albuminemia, mean creatinine, and mean 24hpu levels were 15.56± 5.27 g/l, 17.3 ± 7.6 mg/l, and 6.54 ± 1.13 g/24h, respectively. the median anti-pla2r antibody titer was 100 iu with extremes of 10 and 800 iu. partial remission was noted in three patients at m3 (p2, p4, and p5), and it was maintained until m6 in p2. no complete remission was observed. a significant decrease in mean 24hpu at m3 was noted (p < 0.001). generalized pruritus associated with seizures was noticed in p4 after the first dose of rituximab.conclusions: partial remission was noted in three patients at m3, and one patient maintained this remission at m6. rituximab significantly reduced 24hpu at m3 after administration. rituximab administration was well tolerated by the patients.